Editorial Type:
Article Category: Research Article
 | 
Online Publication Date: 01 Oct 2017

Influence of Bisphosphonates on Implant Failure Rates and Characteristics of Postmenopausal Woman Mandibular Jawbone

DDS,
DDS, PhD,
DDS,
DDS, PhD, and
DDS, PhD
Page Range: 345 – 349
DOI: 10.1563/aaid-joi-D-17-00015
Save
Download PDF

Rehabilitation of oral function using dental implants is clinically effective and highly predictable. Both bone quantity and quality at the implant site affect the success of the procedure. However, the effect of bisphosphonate (BP) use on mandibular bone quality has not been well documented. The purpose of this retrospective cohort study was to evaluate the bone mineral density (BMD) and cortical thickness of the mandible, as well as the influence of BP use on early implant failure. Twenty-five female patients (≥60 years of age) were selected from among 93 candidates with partially edentulous posterior mandibles. Eleven patients had received BP therapy using alendronate (BP group), and 14 patients had received alternate therapy (non-BP group). Cortical and trabecular BMD was measured using quantitative computed tomography. Cortical thickness was measured using computed tomography. The BMDs and cortical thicknesses of the two groups were compared. The results were as follows: (1) Cortical BMD was significantly higher in the BP group, (2) trabecular BMD was not affected by BP use, and (3) Cortical thickness was affected by the duration of BP use. These results indicate that BP use affects the quality and quantity of the cortical bone in the partially edentulous posterior mandible of patients with osteoporosis, which should be considered prior to treatment with dental implants in patients taking BPs.

<bold>
  <sc>Figures 1–3</sc>
</bold>
Figures 1–3

Figure 1. Simultaneous scanning of calibration phantom. Scanning of the bone density calibration phantom with two compartments containing 0 and 200 mg/mL of calcium hydroxyapatite equivalent, respectively, was performed simultaneously with CT scanning of the patients. Figure 2. Region of interest for measuring bone mineral density in the trabecular bone (white marked area). Figure 3. Region of interest for measuring the cortical bone mineral density and thickness (yellow line).


<bold>
  <sc>Figures 4–6</sc>
</bold>
Figures 4–6

Figure 4. Correlation between cortical bone mineral density and duration of bisphosphonate use. Figure 5. Correlation between trabecular bone mineral density and duration of bisphosphonate use. Figure 6. Correlation between cortical bone thickness and duration of bisphosphonate use.


Contributor Notes

Corresponding author, e-mail:munakata@kdu.ac.jp
  • Download PDF